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Venous occlusive diseaseThe drug named deﬁbrotide (DFT) has been studied for many years. It has been shown to possess many
activities: proﬁbrinolytic, antithrombotic–thrombolytic, antiischemic (heart, liver, kidney, skin, brain),
antishock, antiatherosclerotic, antirejection and anti-angiogenic. The previously displayed activities, as
antithrombotic, proﬁbrinolytic and anti-inﬂammatory, suggested its use in vascular disorders, as in the
treatment of peripheral obliterative arterial disease and in thrombophlebitis. Some years after, the use of
DFT in hepatic veno-occlusive disease has been also proposed. Even if DFT was considered for long time a
multi-target drug, now it could be considered on the whole as a drug able to protect endothelium against
activation. The present work reviews the more important experimental and clinical studies performed to
detect DFT effects.
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Once upon a time there was, in the ﬁeld of pharmacology, a domi-
nant concept: “one drug–one activity”. But the accumulating evidences
caused a change in the dominant ideas. The concept of “multi-target
compounds” is now accepted by the scientiﬁc community.
In the present review we report the main experimental and clini-
cal studies that are conducted for the discovery of a drug, named
deﬁbrotide (DFT), which can be considered a multi-target compound
as well. It has a host of activities; however, if you consider DFT as a
drug able to limit endothelial cell activation, each piece of the puzzle
will neatly ﬁt into its right place, and the host of activities becomes
an array of activities. In fact the polyhedric inﬂammatory process is
the common background of seemingly different illnesses, both acute
and chronic. We come full circle: one drug, DFT–one activity, anti-
endothelial cell activation activity (Fig. 1).2. The history of deﬁbrotide
The history of DFT began in 1968 when in Crinos' raw material de-
partment a fraction, containing phosphorus, was isolated from animal
tissues. This fraction was called “Fraction P”, the ﬁrst name of DFT.
DFT's proﬁbrinolytic activity was the ﬁrst activity to be unraveled,
thanks to the efforts of Mantovani (Pescador et al., 1983) and other
authors (Porta et al., 1991; Mussoni et al., 1979; Klocking, 1992).
Niada discovered the second set of DFT's activities that is its
antithrombotic and thrombolytic activities (Niada et al., 1981, 1982).
Later this subject was explored in more detail by Fumagalli (Fumagalli
et al., 1987, 1989), Breddin (Giedrojc and Breddin, 1991), Pescador
(Tettamanti et al., 1992), Page (Paul et al., 1993), and Grodzinska
(Grodzinska et al., 1987).
In 1982 Niada started a series of seminal experiments of myocar-
dial infarction in a cat (Niada et al., 1985, 1986) which attracted in-
vestigators in this ﬁeld both in Italy and abroad. All of them
generated an astonishing amount of work outlining and clarifying
the cardioprotective activity of DFT in both “in vitro” and “in vivo”
animal models and in different animal species (Berti et al., 1986,
1987a, 1987b, 1988, 1990a, 1992, 1993; Hohlfeld et al., 1991, 1993;
Lefer et al., 1990; Lobel and Schror, 1985; Radice et al., 1997;
Rossoni et al., 1996, 1999b, 2000 Schror et al., 1989; Shin et al.,
1998; Thiemermann et al., 1985, 1989).Platelet
activation (via cAMP)
Weibel Palade bodies
(containing P-selectin) release
(-)PAF (+)TFPI
Defibrotide
(-)TXA2
(-)Thrombin
Fig. 1. Activities of deﬁbrotide. Factors involved in coagulation are depicted un yellow; in gree
area factors involved in platelet activation. Inhibition; (+) increase or (−) decrease. Green aDFT anti-ischemic activity was demonstrated in the kidney and in
the liver too, by Bianchi (Berti et al., 1991), Rigotti (Ferraresso et al.,
1993) and Ferrero (Ferrero et al., 1990) respectively.
Lefer was the ﬁrst to discover and describe DFT anti-shock activity
in different shock models (Aoki et al., 1988; Bitterman et al., 1988; Ma
et al., 1991), followed by Schrör and Nowak (Hohlfeld et al., 1992),
who were the ﬁrst to claim DFT activity in multi organ failure (MOF).
The anti-atherosclerotic activity of DFT was mainly described by
Pescador (Pescador et al., 1989; Pescador et al., 1995), Schrör (Schror
et al., 1989) and Porta (Porta et al., 1994). Kahan (Ferraresso et al.,
1993) and Ferrero (Ferrero et al., 1994) discovered and described DFT
anti-rejection activity.
While the stream of the main DFT activities (at whole body or
organ level), summarized above, was running, lots of activities both
at cellular and molecular level were discovered and described as well.
Schrör (Bracht and Schror, 1994; Lobel and Schror, 1985, 1989), and
Pescador (Pescador et al., 1995) found an evidence of antiplatelet activ-
ity of DFT, while Schrör (Hohlfeld et al., 1993; Schror et al., 1989), Lefer
(Scalia et al., 1996a) and Rossoni (Rossoni et al., 1996) described its anti
polymorphonucleate leukocyte (PMN) activity. Fumagalli, Pescador and
Kahan discovered DFT anti leukocyte activity (Ferraresso et al., 1993;
Fumagalli et al., 1987; Fumagalli et al., 1989; Pescador et al., 1995). As
far as DFT activities at molecular level are concerned, we have to
quote the seminal work of Niada,whoﬁrst suggested that DFT increases
the generation of prostacyclin I 2 (PGI 2) (Niada et al., 1981). This sug-
gestion paved the way for the work of Schrör (Hohlfeld et al., 1992;
Lobel and Schror, 1985, 1989; Schror et al., 1989), Berti (Berti et al.,
1990b, 1993), Lefer (Bitterman et al., 1988), Rossoni (Rossoni et al.,
2006) and Gryglewski (Gryglewski et al., 1989) on the ability of DFT
to increase the generation of PGI2. In particular Berti discovered that
DFT, besides increasing PGI2 generation, increases prostaglandin E 2
(PGE2) generation as well (Berti et al., 1988) and Schrör discovered
that it decreases thromboxane A 2 (TXA2) generation (Bracht and
Schror, 1994; Hohlfeld et al., 1992). Later Coccheri (who performed
many clinical studies) discovered that DFT decreases the generation of
leukotriene B 4 (LTB4) and Berti and Maclouf discovered that DFT
decreases that of cysteinyl leukotrienes (CYSLT) (Rossoni et al., 1996).
The list of DFT activities at molecular level goes on, showing the follow-
ing properties of the drug: cyclic adenosine monophosphate (cAMP)
increase in platelets, decrease of platelet activating factor (PAF) gener-
ation (Berti et al., 1990a), antagonism towards endothelin-1 contractile
activity (Berti et al., 1990b), effect on nitric oxide (NO) increase (BertiICAM1
(+)TM
(-)CysLT
(-)VEGF
(+)NO (+)PGI2 & PGE2
(-)Endothelin1(-)PAI
(+)FPA
LFA1
n area factors released from EC; in orange area factors involved in EC activation; in purple
rrow = activation; red arrow = production.
Table 1
The most important activities of deﬁbrotide are reported.
DEFIBROTIDE ACTIVITIES
Inﬂammation and vascular
permeability
• Reduces cysteinyl leukotriene release
• Reduces NFkB activation (bone marrow)
displaying antiinﬂammatory function.
• Reduces platelet activation
Leukocyte adhesion molecules • Downregulates P-selectin expression.
• Interferes with ICAM1/LFA1 system
Antithrombotic and
thrombolytic effects
• Increases tPA, TFPI, TM
• Reduces: PAI, PAF, thrombin
Mediator/cytokine production • Increases PGE2 and PGl2
• Reduces IL-6
• Reduces VEGF
• Reduces TXA2
• Reduces LTB4
• Reduces TNF
Regulation of HLA molecules • Downregulates MHCI molecule expression
• Reduces MHCII expression
Vascular tone • Antagonizes endothelin I
• Increases NO and NOS
3R. Pescador et al. / Vascular Pharmacology 59 (2013) 1–10et al., 1993; Masini et al., 1995), and anti tumor necrosis factor alpha
(TNFα) activity (Schroder, 1995). Now let us look at some proteins in
the blood and vascular wall and DFT effects on them. DFT increases
tissue plasminogen activator (t-PA) and decreases plasminogen activa-
tor inhibitor (PAI) (Klocking, 1992). Fareed's work's main ﬁnding was
to give evidence that DFT increases tissue factor pathway inhibitor
(TFPI) (Cella et al., 2001). We have to quote the work of Ruan on the
increase of thrombomodulin (TM) (Zhou et al., 1994). Ferrero and
Lefer described DFT interference on leukocyte–endothelial cell inter-
action mediated by some adhesion molecules, as intercellular adhe-
sion molecule/lymphocyte function associated antigen (ICAM-1/LFA-1)
(Pellegatta et al., 1996) and P-selectin expression (Scalia et al., 1996a).
DFT inhibits cytosolic calcium increase (Bracht and Schror, 1994). At
last a look at some DFT molecular structures involved in some of its ac-
tivities was achieved; DFT, through aptamers (GGTTGG ATT GGTTGG
AND GGTTGG ATC GGTTGG) has been shown able to inhibit thrombin
(Bracht and Schror, 1994), as well as cathepsin G (CATG) (Evangelista
et al., 1992a), through a recurrence of alternating TG repeats (Gatto
et al., 2008).
3. Deﬁbrotide chemistry
Deﬁbrotide is a mixture of 90% single-stranded phosphodiester
oligonucleotides (length, 9-80mer; average, 50mer; average molec-
ular mass, 16.5 ± 2.5 KDa) and 10% double stranded phosphodiester
oligonucleotides derived from the controlled depolymerization of
porcine intestinal mucosal DNA (Corbacioglu et al., 2012; Espinosa
et al., 2011; Francischetti et al., 2012). That is, generally speaking,
a heparin-like situation. Inside this mixture of oligonucleotides,
aptamers (GGTTGGATTGGTTGG and GGTTGGATCGGTTGG) able to
inhibit thrombin were discovered (Bracht and Schror, 1994). Later
in a study carried out to discover inside deﬁbrotide cathepsin G
inhibiting aptamers the following consensus sequences were found:
GGN1–7GGN8–14GGN1–6GGN1–7GGN1–6GG,GGN10–13GGN1–5GGN1–5GGN3–6
GGN2–7GG and the sequence GGGTTGAGGGTGGATTACGCCACGT-GGA
GCTCGGATCCACACATCCAGG, wherein N represents nucleotides and the
ﬁgures represent the number of possible nucleotides at that site. More re-
cently a second study, aimed atﬁnding effective inhibitors of Cathepsin G,
showed a recurrence of alternating TG repeats in the selected Cat G
binders, adopting an extended conformation that grantsmaximal interac-
tionwith the highly charged protein surface (Gatto et al., 2008). Synthetic
TG oligonucleotides of different length were tested to assess the de-
pendence of Cat G binding on oligonucleotide length. (dT-dG)60 and
(dT-dG)50 appeared to bemore potent binders than (dT-dG)40. Cat G rec-
ognition is poorer with 20–30 mer oligonucleotides (Gatto et al., 2008).
All of the above is, generally speaking a heparin-like situation. Heparin
is a mixture of chains of different length in which there are binding sites
for the thrombin–antithrombin complex.
4. Pharmacokinetics
A study, carried out, by single oral or intravenous administration
of [125I]-DFT, to man gave results, for radioactivity associated with
DFT or related components, very close to those, previously obtained,
in rats, by an administration of [125I]-DFT and [32P]-DFT, respec-
tively, that is: half life of the distribution phase (T1/2α) in the
range of minutes, half life of the elimination phase (T1/2β) in the
range of hours, bioavailability in the range of 50–70% (Fisher et al.,
1993, 1996).
5. The consistent picture of deﬁbrotide activities
What do all of the above activities have to do with a single drug?
In 1998 Hunt and Jurd (Hunt and Jurd, 1998) wrote: (Endothelial)
“Activation entails a stereotyped series of processes although their
effects are diverse and are seen differently by specialists in differentdisciplines. Immunologists study up-regulation of surface antigens
and adhesion molecules while those in thrombosis research assess
pro-thrombotic endothelial cell changes, and vascular biologists
study changes in tone. All these effects however are components of
endothelial cell activation and mutually interact in causing local in-
ﬂammation”. Endothelial cell activation seems to be a common path-
ogenic mechanism because it is induced by a wide range of agents
such as certain bacteria and viruses, interleukin 1 (IL-1) and TNF,
physical and oxidative stress, oxidized low density lipoproteins,
anti-endothelial cell antibodies (Hunt and Jurd, 1998) (found in
systemic autoimmune diseases such as vasculitis, systemic lupus
erythematosus (Tsokos, 2011) and antiphospholipid syndrome (Hunt
and Jurd, 1998)), ischemia–reperfusion (Tsao et al., 1990), hemorrhagic
shock (Barroso-Aranda et al., 1995), traumatic shock (Scalia et al.,
1996b), malignancy and complications of pregnancy (Periti, 2000).
Endothelial cell activation is a graded rather than an all-or-nothing
response; for example, changes in endothelial cell integrity range
from simple increases in local permeability to major endothelial cell
contraction exposing large areas of sub-endothelium (Hunt and Jurd,
1998). Activationmayoccur locally (Hunt and Jurd, 1998) or systemically
(Hunt and Jurd, 1998; Kleinschmidt et al., 1998; Shayevitz et al., 1995)
and this last systemic widespread inﬂammatory host response to vari-
able insults is the patho-physiological basis of MOD and/or multi organ
failure (MOF) (vanGriensven et al., 2006).MOD/MOF has nowbeen doc-
umented as a complication in a variety of infectious or non-infectious
conditions such as acute pancreatitis, major surgery, hemorrhage, severe
trauma, ischemia, burns and hypovolemic shock (Fortin et al., 2010;
Parrillo, 1993). Mortality almost uniformly approaches 90%–100% when
three or more organ systems fail. In a large-scale multicenter study 99
patients had three or more failing organ systems after 72 h of intensive
therapy, of whom only two survived (Knaus et al., 1985). In the USA,
the condition develops during 15% of all intensive care unit (ICU)
admissions; it is responsible for up to 80% of all ICU deaths and results
in ICU costs of more than $ 100,000 per patient or about $ 500,000 per
survivor. Endothelial cell activation is also a key event in an unnatural
situation as xeno-transplantation (Bach et al., 1995). It has been
shown “in vitro” that human xenoreactive natural antibodies and com-
plement as well as other mediators activate porcine endothelial cells
with resultant coagulation and platelet aggregation, which aremanifes-
tations of thrombosis. Endothelial cell activation is also seen with rejec-
tion “in vivo” accompanied by inﬂammation and thrombosis, the very
complications associated with xenograft rejection (Bach et al., 1995)
(Table 1).
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activation are:
• loss of vascular integrity;
• expression of leukocyte adhesion molecules;
• change in phenotype from anti-thrombotic to pro-thrombotic;
• cytokine production;
• up-regulation of human leukocyte antigen (HLA) molecules;
• changes in vascular tone.
Loss of vascular integrity can expose sub-endothelium and cause the
efﬂux of ﬂuids from the intravascular space (Hunt and Jurd, 1998).
Up-regulation of leukocyte adhesion molecules such as E-selectin,
ICAM-1, and vascular cell adhesion molecule-1 (VCAM-1) allows leu-
kocytes to adhere to endothelium and then move into the tissues
(Hunt and Jurd, 1998), through a concerted action of other mediators
such as TXA2, LTB4 (a potent chemotactic agent that initiates, coordi-
nates, sustains and ampliﬁes the inﬂammatory response (Devchand
et al., 1996)), CYSLT (Rossoni et al., 1996), PAF and activated comple-
ment products and histamine (Kubes and Ward, 2000).
The pro-thrombotic effects of endothelial cell activation include
loss of the surface anticoagulant molecules TM and heparan sulphate,
and down-regulation of the activation of protein C pathway. In this
regard, new-born infants totally deﬁcient in protein C suffer from
extensive thrombosis with inﬂammation in the microvasculature
(Grifﬁn, 1995), reduced ﬁbrinolytic potential due to enhanced PAI
type 1 release, loss of the platelet anti-aggregating effects of ecto-
adenosine diphosphate phosphatases (ecto-ADPases) and PGI2, pro-
duction of PAF and expression of tissue factor (TF) (Cicala and
Cirino, 1998; Hunt and Jurd, 1998).
Cytokine synthesis occurred, including TNF, IL-1 and
interleukin-6 (IL-6), as well as synthesis of chemokines, such as
interleukin-8 (IL-8), monocyte chemoattractant protein 1 (MCP-1)
(Hunt and Jurd, 1998; Ross, 1999) and platelet derived growth
factor-BB (PDGF-BB) (Ross, 1993).
Expression of class II HLA molecules allows endothelial cells to act
as antigen presenting cells (Hunt and Jurd, 1998; Ross, 1993, 1999).
High levels of MHC class II cell surface receptor (HLA-DR) are present
on the endothelium of the vessels from transplanted hearts (Ross,
1999). Inﬂammation is a defensive host response to numerous differ-
ent forms of insult, and ideally it should last for a short time and be a
very localized response as it operates through deadly cells and sub-
stances (Smith, 1994; Weiss, 1989). When this defensive host response
lasts for decades and becomes excessive, the intended protection be-
comes a disease entity in itself, as happens in chronic inﬂammatory dis-
eases such as cirrhosis, rheumatoid arthritis (McInnes and Schett, 2011;
Sattar et al., 2003; Sattar and McInnes, 2005), glomerulosclerosis,
pulmonary ﬁbrosis, chronic pancreatitis (Ross, 1999) and, particularly,
in atherosclerosis (Devchand et al., 1996; Pasceri and Yeh, 1999; Ross,
1993, 1999); in this last instance some talk about endothelial dysfunc-
tion (Busse and Fleming, 1996; Celermajer, 1997; Valdivielso et al.,
2008), some of endothelial activation (Carluccio et al., 1999), and
some of both of them (Chiba et al., 2001). So seemingly different disor-
ders, for instance cardiovascular disease, rheumatoid arthritis, psoriasis
and pre-eclampsia share a common background: inﬂammation (Barnes
and Karin, 1997; Devchand et al., 1996; Pasceri and Yeh, 1999; Redman
and Sargent, 2005; Ross, 1999).
6. Pharmacological properties of DFT: experimental studies
6.1. Loss of vascular integrity
DFT is active in local Shwartzman reaction (Niada et al., 1982), a
model that involves close interaction between the inﬂammatory and
hemostatic pathways (Subramaniam et al., 1996) and in carragenin-
induced pleurisy. Short oligodeoxynucleotides containing nuclear fac-
tor kB (NFkB) binding sites are effective in models of acute and chronicinﬂammation (Makarov, 2000), which is related to increase in vascular
permeability. DFT abrogates NFkB activation in multiple myeloma and
bone marrow stromal cell (Mitsiades et al., 2009). DFT decreases
the generation of CYSLT (Rossoni et al., 1996) which may be involved
as causative agents of pathologic vascular permeability (Cook and
Halushka, 1989; Pfeifer et al., 1991; Rossoni et al., 1996). DFT deacti-
vates platelets (Francischetti et al., 2012; Scalia et al., 1996a)which con-
tribute to increased vascular permeability (Cicala and Cirino, 1998). DFT
is active through aptamers, against thrombin (Scalia et al., 1996a)
which enhances vascular permeability (Goldsack et al., 1998). DFT de-
creases the generation of TNF, which induces vascular permeability
(Ferrero et al., 2001).
6.2. Expression of leukocyte adhesion molecules
DFT decreases leukocyte extravasation (Hohlfeld et al., 1993; Shin et
al., 1998). DFT down-regulates P-selectin expression (Scalia et al.,
1996a) (platelets, like leukocytes, roll on activated endothelium, and
this rolling is mediated by P-selectin expressed on activated endotheli-
um (Subramaniam et al., 1996)) and interferes with ICAM-1/LFA-1 ad-
hesion system (Pellegatta et al., 1996). DFT decreases the generation of
LTB4, one of the most powerful chemoattractants known (Devchand
et al., 1996), provoked by histamine. P-selectin is induced in minutes
in response to histamine (Kubes and Ward, 2000), CYSLT (Rossoni et
al., 1996) (which enhance PMN adhesiveness (Damtew and Spagnuolo,
1997)), TXA2 (Hohlfeld et al., 1992; Scalia et al., 1996a) and PAF (Berti
et al., 1990a), which directly primes superoxide generation and elastase
release (Smith, 1994) from PMNs. DFT inhibits, probably through
aptamers and/or a recurrence of alternating TG repeats (Gatto et al.,
2008), CATG (Evangelista et al., 1992b), the main biochemical mediator
of PMN–platelet cooperation (Evangelista et al., 1992b). DFT has,
through aptamers, antithrombin activity (Bracht and Schror, 1994).
In response to thrombin, P-selectin is rapidly redistributed from
the membranes of Weibel–Palade bodies to the endothelial surface
(McEver, 2001). DFT increases the generation of PGE2 (Berti et al.,
1988) and PGI2 (Berti et al., 1988, 1990a; Bitterman et al., 1988;
Gryglewski et al., 1989; Hohlfeld et al., 1992; Lobel and Schror,
1985), which suppress neutrophil activation (Smith, 1994), and
favors the generation of NO (Masini et al., 1995). Accordingly, the
NO synthase inhibitor L-arginine reduces endothelial expression of
ICAM-1 and VCAM-1 (Adams et al., 1997).
DFT suppresses the increased gene expression of ICAM-1 in human
microvascular endothelial cells (Mitsiades et al., 2009). DFT antago-
nizes, as well, the effect of metabolite of ﬂudarabine (F-Ara), a strongly
immunosuppressive purine analog with considerable anti-neoplastic
and immunosuppressive activity. It also prevents the activation of
macrovascular and microvascular endothelia caused by soluble factors
released to blood by autologous hematopoietic stem cell transplanta-
tion (HSCT) (Eissner et al., 2002; Palomo et al., 2011).
TNF can promote the expression of adhesion molecules in endothe-
lial cells whichmediate the adherence of leukocytes to the endothelium
also in the instance of reperfusion injury in the heart (Kupatt et al.,
1999). DFT decreases the generation of TNF. Interaction of TNF with
neutrophils triggers an increased expression of surface adherence gly-
coproteins, increase in of superoxide production, phagocytosis, enzyme
release and aggregation of these cells. DFT increases the generation of
protein C as well as inhibits neutrophil activation (Murakami et al.,
1996). DFT inhibits O2− andβ-glucuronidase release fromhuman stim-
ulated neutrophils (Schror et al., 1989). Since the activation of A2 recep-
tors on neutrophils reduces their adherence, inhibiting the release of
reactive oxygen species, DFT acts as an adenosine A2 receptor agonist
(Bianchi et al., 1993). The abovemechanism is conﬁrmed byDFT inhibi-
tion of toll-like receptor ligand-dependent dendritic cell activation,
by a mechanism that is blocked by the adenosine receptor antagonist
8-p-sulfo-phenyltheophylline, but not reproduced by synthetic poly-
A,-C,-T and G. These results imply that aptameric sequences and
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sponse to the drug.
Thrombin is formed following tissue injury. It promotes, besides
the conversion of ﬁbrinogen to ﬁbrin, many cellular effects, including
chemotaxis (monocytes and neutrophils), adhesion molecule expres-
sion, release of cytokines (Goldsack et al., 1998) and platelet aggrega-
tion (Goldsack et al., 1998). DFT has anti-thrombin activity (Bracht
and Schror, 1994). DFT is active in leukocyte-dependent reperfusion
injury models (Rossoni et al., 1996; Shin et al., 1998) in which endo-
thelial activation is a strategic event during post-ischemic myocardial
inﬂammation (Kupatt et al., 2000).
6.3. Change in phenotype from anti-thrombotic to pro-thrombotic
Venous thrombosis is associated with inﬂammation (Blann et al.,
2000; Butenas et al., 2009; Downing et al., 1997; Henke et al., 2000;
Wakeﬁeld et al., 1995, 2000) and new-born infants totally deﬁcient
in protein C suffer from extensive thrombosis with inﬂammation
(Grifﬁn, 1995). DFT has anti-thrombotic–thrombolytic activity in
several different experimental models (Fumagalli et al., 1987;
Fumagalli et al., 1989; Giedrojc and Breddin, 1991; Grodzinska
et al., 1987; Niada et al., 1981, 1982; Paul et al., 1993; Tettamanti
et al., 1992). DFT increases TM (Zhou et al., 1994), protein C plasmin
activity, t-PA (Echart et al., 2012; Klocking, 1992), TFPI (Cella et al.,
2001), which is also endowed with anti-inﬂammatory properties
effects (Bajaj et al., 2001), PGI2 (Berti et al., 1988, 1990a; Hohlfeld
et al., 1992; Lobel and Schror, 1985; Rossoni et al., 2006), PGI2 recep-
tors on the surface of platelets and their afﬁnity for PGI2 (Lobel and
Schror, 1989), production of NO (Masini et al., 1995) and nitric
oxide synthase (NOS) activity. DFT decreases PAF (Berti et al.,
1990a), PAI (Klocking, 1992), TF (Falanga et al., 2003; Francischetti
et al., 2012), which represents the link between inﬂammation and
thrombosis (Penn and Topol, 2001) and TXA2 (Bracht and Schror,
1994; Hohlfeld et al., 1992). Coagulation is activated after the
administration of TNF (Penn and Topol, 2001). DFT decreases the
generation of TNF which causes the release of pro-coagulant TF
from endothelial cells (Szotowski et al., 2005) as well as of thrombin
(Scalia et al., 1996a) which induces endothelial TF expression
(Viswambharan et al., 2004). DFT deactivates platelets (Bracht
and Schror, 1994), monocyte/macrophages (Cirillo et al., 1991;
Tettamanti et al., 1992) and PMNs (Hohlfeld et al., 1991; Scalia
et al., 1996a; Schror et al., 1989; Shin et al., 1998). Leukocytosis
and thrombocytosis are decreased by DFT (Pescador et al., 1995).
DFT decreases leukocyte and platelet aggregates in thrombi (Fumagalli
et al., 1987; Fumagalli et al., 1989). DFT attenuates complement activa-
tion (Francischetti et al., 2012) which is responsible to contribute to
thrombosis (Kourtzelis et al., 2010). The ability of DFT to exert protec-
tive effects in different models of tissue and organ ischemia suggested
also that it functions as a possible anti-ischemic drug (Coccheri and
Nazzari, 1996), as conﬁrmed by its anti-rejection activity.
6.4. Mediator/cytokine production
TNF is decreased by DFT. Endothelial cells are protected from
TNFα noxius effects by DFT (Schroder, 1995). DFT counteracts the mi-
togenic activity of PDGF-BB. DFT increases the generation of PGE2 and
PGI2 (Berti et al., 1988, 1990a; Gryglewski et al., 1989; Hohlfeld et al.,
1992; Lobel and Schror, 1985) which inhibit IL-1 and interleukin-2
(IL-2) production (Ferraresso et al., 1993) and decreases the genera-
tion of TXA2 (Bracht and Schror, 1994; Hohlfeld et al., 1992) and
LTB4 which enhance T cell proliferation (Ferraresso et al., 1993).
LTB4 stimulates IL-1 and IL-2 production (Ferraresso et al., 1993).
DFT normalizes elevated levels of IL-2. DFT suppresses the increase
in secretion of IL-6 or vascular endothelial growth factor (VEGF)
(Mitsiades et al., 2009). The vertebrate DNA is able to inhibit cytokine
release from plasmid-triggered spleen cells (Wloch et al., 1998).Indeed, it has immune inhibitor activity (Hacker, 2000; Krieg et al.,
1998). In fact DFT inhibits dendritic cell activation (Francischetti
et al., 2012).
6.5. Regulation of human leucocyte antigen (HLA) molecules
DFT increases PGE2 and PGI2 generation (Berti et al., 1988, 1990a;
Gryglewski et al., 1989; Hohlfeld et al., 1992; Lobel and Schror, 1985).
PGE2 and PGI2 are known to decrease major histocompatibility com-
plex (MHC) class II antigen expression (Ferraresso et al., 1993).
F-Ara, up-regulates MHC class I molecules. DFT down-regulates
MHC class I molecule expression (Eissner et al., 2002). DFT either
does not affect (Thiemermann et al., 1985) or actually reduces the
synthesis of pro-rejection arachidonic acid metabolites thromboxane
B2 (TXB2) and TXA2, respectively (Bracht and Schror, 1994; Hohlfeld
et al., 1992). The above situation should promote graft acceptance
(Ferraresso et al., 1993). Actually DFT prolonged the survival of trans-
plant “in vivo” (Corsi et al., 1993; Ferraresso et al., 1993; Ferrero et al.,
1994).
6.6. Changes in vascular tone
DFT antagonizes the vasoconstrictor activity of endothelin-1 (Rossoni
et al., 1999a, 2000). Endothelin-1 is increased in inﬂammatory diseases
as atherosclerosis and rheumatoid arthritis (Pasceri and Yeh, 1999).
Atherosclerosis worsens relaxation (endothelium- and NO-dependent)
to acetylcholine (Freiman et al., 1986; Hathaway et al., 2002). DFT coun-
teracts atherosclerosis and noxious effects on vessel relaxation (Rossoni
et al., 1999a, 2000). DFT increases the generation of NO (Masini et al.,
1995) and NOS activity. Endothelial cell activation is inhibited by NO
donors (Zampolli et al., 2000). The reduction in reactive oxygen species
formation by DFT (Cirillo et al., 1991) would act to enhance the bioavail-
ability of NO and thus potentiate the effectiveness of endothelium-
generatedNO (Lefer et al., 2001). DFT remarkably increases PGI2 produc-
tion and reduces TXB2 levels (Rossoni et al., 2006).
7. Pharmacological properties of DFT: clinical studies
After the above detailed overview of DFT activities and action
mechanism, now let us address a more practical issue: is DFT useful
to humans?
7.1. Anti ischemic and antithrombotic activities
Some clinical results, especially in ischemic and microthrombotic
conditions, have been previously revealed positive or promising
(Coccheri and Biagi, 1991). In the past DFT has been used in the ther-
apy of vascular disorders (Palmer and Goa, 1993). However, more re-
cently also, in the PROVEDIS study, treatment with DFT in addition to
elastic compression in patients with objectively assessed chronic
deep vein insufﬁciency, mostly due to post-thrombotic syndrome,
resulted in clinical beneﬁts and prevented thrombotic complications
harmful to the limb conditions (Coccheri et al., 2004). Moreover,
DFT activity in peripheral arterial disease ﬁts this scenario as well.
In the DICLIS study (a double blind placebo controlled study), long-
term administration of oral DFT improved the walking distance in
patients with intermittent claudication (Violi et al., 2000).
7.2. Treatment of VOD
Now, DFT is proposed for treatment of patients with MOD/MOF or
severe VOD.
Indeed, as reported above, endothelial cell activation may occur
locally (Hunt and Jurd, 1998) or systemically (Hunt and Jurd, 1998;
Kleinschmidt et al., 1998; Shayevitz et al., 1995) (this last condition
is responsible for an estimated 100,000 deaths a year in the USA
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ﬂammatory host response is the patho-physiological basis of MOD.
Hence one could hypothesize that DFT is active in MOD/MOF and,
actually, that was the case: in animals, 88% of pigs with MOF, treated
with DFT, survived the otherwise lethal situation (Hohlfeld et al.,
1992). In humans, the studies were performed in patients with ve-
nous occlusive disease (VOD). VOD is a life-threatening complication
of high dose chemo/radiotherapy and human stem cell transplanta-
tion (HSCT) characterized by injury and inﬂammation to sinusoidal
endothelial cells of the liver. It is also known as sinusoidal obstruction
syndrome (SOS) (DeLeve et al., 2002; Shulman et al., 1994). The oc-
currence of clinical VOD presents disparity in incidence, depending
on the type of transplant, conditioning therapies, patient-related
risk factors and the criteria for diagnosis. Complications after bone
marrow transplantation (BMT) are manifestations of systemic inﬂam-
matory response syndrome (Evans and Smithies, 1999; Takatsuka
et al., 2000), that is endothelial cell activation and inﬂammation
were evidenced in MOF (Richardson et al., 2002); 35% of DFT treated
patients displayed complete resolution and survival past day +100
(Richardson et al., 2002). The above results were conﬁrmed by the
European compassionate-use study: 22 out of 40 evaluable patients
with VOD achieved a complete response to DFT and resolution of
signs/symptoms of VOD and end-organ dysfunction (EOD) (Chopra
et al., 2000). In the subgroup of patients with either evidence of
MOF or who met risk criteria predicting fatality, 10 out of 28 patients
showed a complete response (Chopra et al., 2000). In this study 43%
of patients were alive beyond day +100 (Chopra et al., 2000). Four
of 8 patients with VOD, treated with DFT, were alive past 3 months
and one woman with VOD, treated with DFT, was in excellent clinical
condition at 6 months after the onset of liver VOD.
In a randomized phase II doseﬁnding study, in severe (VOD + MOF)
VOD patients, following HSCT, DFT was given at either 25 mg/kg day
(n = 75) or 40 mg/kg/day (n = 74) by intravenous route. Survival
rates at day +100, post HSCT, were 46% and 42% respectively with
no signiﬁcant difference between treatment arms (Richardson et al.,
2010). Four patients with SOS and evidence of MOF were treated with
iv. DFT and 75%of patients responded to therapy (Yakushijin et al., 2005).
Following HSCT, 71 children did not receive any speciﬁc VOD
prophylaxis or therapy (controls). Other 91 children were given
anti-thrombin III (AT III) replacement, in the case of decreased AT III
activity (ﬁrst group). If VOD was diagnosed clinically, high dose DFT
and AT III therapy were combined (second group). The severity of
VOD was determined according to the degree of MOD. The incidence
of VOD was similar in both groups (13/71, 18% vs. 14/91, 15%). All 14
patients with VOD, receiving combined therapy, achieved complete
remission and 93% (13/14) survived until day +100, compared to
six survivors (46%) of ﬁrst group (Haussmann et al., 2006).
DFT was active even when given by oral route to a patient with
late-onset VOD, post autologous peripheral stem cell transplantation,
with complete resolution of VOD by day +75 (Shah et al., 2009).
After the diagnosis of SOS, 14 patients, following HSCT, received
DFT. The overall response rate was 78.56%, while it was 50% in severe
SOS cases (Sucak et al., 2007).
Similarly, 14 children with VOD, following HSCT, received DFT at a
mean dose of 33 mg/kg for a mean period of 16 days. The survival
rate to day +100 was 79% (Bulley et al., 2007).
Of 180 pediatric patients, the 12%, with one or more risk factors
for VOD, randomly allocated to the prophylactic DFT treatment, had
VOD by 30 days after HSCT, compared with 20% of 176 controls
(Corbacioglu et al., 2012).
Besides VOD, another vascular endothelial complication following
stem cell transplantation is thrombotic microangiopathy (TMA)
(Stavrou and Lazarus, 2010) which includes: hemolytic uremic
syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP)
(Murrin andMurray, 2006).Mortality rate in TMA, associatedwith trans-
plantation, ranges between 60% and 90% (Stavrou and Lazarus, 2010).Five of 6 patients treated with DFT shoved a complete response and
resolution of signs/symptoms of VOD and end-organ dysfunction and
they were alive at day +100. Of 10 patient displaying episodes of
HUS/TTP, treated with DFT, 6 showed complete resolution of HUS/TTP.
Twelve patients underwent BMT. TTP was mild in two patients
and severe in 10 with central nervous system (CNS) dysfunction,
renal impairment, gut or bladder bleeding and MOF. DFT was beneﬁ-
cial in about 50% of the patients who showed a good response to drug
(Corti et al., 2002).
In some patients affected by acute renal failure, coagulation abnor-
malities (low platelet count, high levels of ﬁbrin degradation products)
and neurological manifestations, DFT administration caused disap-
pearance of neurological manifestations and normalization of coagu-
lation parameters. All patients are alive at 7–22 months of follow-up
(Bonomini et al., 1985).
In anti-phospholipid antibody syndrome (APS) endothelial cells
are perturbed (Rand, 2002) and one mechanism that proposed to
account for this unusual pro-thrombotic state is the activation of en-
dothelial cells by anti-phospholipid antibodies (Williams et al., 2000)
as well as injury to endothelium and platelet activation (Rand, 2002):
activation of endothelial cells enhance the expression of ICAM-1,
VCAM-1 and P-selectin (Pierangeli et al., 2001). DFT was active in
2 out of 2 patients with APS, normalizing increased levels of
endothelin-1, IL-2, TNF and PAI. Hypertension, impaired platelet
aggregation and abnormal bleeding time were normalized by DFT
as well.
More recently DFT prophylaxis has been shown to reduce inci-
dence of VOD in pediatric HSCT (Corbacioglu et al., 2012).
In conclusion, DFT may be effective in the prophylaxis and treat-
ment of VOV (Guglielmelli et al., 2012).
7.3. Effects of DFT on tumor angiogenesis
Twenty four patients with relapsed/refractory multiple myeloma
were enrolled and given melphalan, prednisone and thalidomide.
DFT was administered orally. In all patients, the complete response
plus very good partial response rate was 9% and the partial response
rate was 43%. The 1 year progression-free survival and 1-year overall
survival rates were 34% and 90% respectively (Palumbo et al., 2010).
These data were conﬁrmed by an “in vitro” study in which DFT was
able to protect endothelial cells by thalidomide-mediated cell death
without interfering with its anti-tumor effect (Echart et al., 2012).
In another set of experiments DFT “in vitro” reduced vessel forma-
tion. Similarly DFT blocked sprouting from cultured rat aortic rings.
Angiogenesis was also blocked “in vivo” in a model of nude mice
(Koehl et al., 2007). It was proposed that DFT directly interferes
with migration and tube formation of endothelial cells which is
dependent on mTOR-p70S6k activity (Koehl et al., 2007).
VOD occurred in 5 of 35 patients with Wilms tumor, treated with
chemotherapy. Two patients developed MOF. Three patients were
treated with DFT, while two patients received supportive measures
only. Four patients recovered, three of them had received DFT. They
are all alive and well after 35 months (Cesaro et al., 2011). One of
two patients not treated with DFT died of MOF (Cesaro et al., 2011).
The obtained results suggest that DFT may belong to the new
generation of anti-cancer drugs that can prevent tumor angiogenesis.
In multiple myeloma, DFT may overcome the pro-thrombotic effect of
thalidomide on endothelial cells (Guglielmelli et al., 2012).
8. Discussion and concluding remarks
Taken globally the seemingly different DFT activities [pro-ﬁbrinolytic,
anti-thrombotic-thrombolytic, anti-ischemic (heart, liver, kidney), anti-
shock and anti-atherosclerotic] ﬁt a more global anti-endothelial cell
activation activity.
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1994) DFT could represent a natural library of oligonucleotides butwith
some boundaries. The boundaries are that, being DFT derived from
nuclear DNA, it must not have any stimulatory activity on the immune
system (Hacker, 2000; Krieg et al., 1998; Wloch et al., 1998).
The boundaries are derived from the constraints imposed by evo-
lutionary pressures which had to assure both a working genetic infor-
mation and lack of immune stimulatory activity in the instance of
nuclear DNA breakdown when a body cell dies. In this contest verte-
brate DNA is not an immuno-stimulator, in fact it is able to inhibit
cytokine release from plasmid-triggered spleen cells (Wloch et al.,
1998). Hence to expect that DFT could contain aptamers good for
any pharmacological task, could be out of any evolutionary stand-
point. Actually we do have to expect that DFT has activities addressed
to dampen and eliminate any inﬂammatory activity.
From the data, so far collected in animals and humans, it appears
that DFT is useful in those diseases, the underlying pathology of
which is systemic endothelial activation and inﬂammation.
The concept of multi-target compound has emerged in the ﬁeld of
inﬂammation (Celotti and Laufer, 2001). For many years the beneﬁ-
cial effects of the statins were attributed to their cholesterol lowering
effect. But statins were found to exert other activities. They are anti-
oxidant, anti-thrombotic and vasculo-protective, for instance (Lefer
et al., 2001). Last but not least DFT directly interferes with migration
and tube formation of endothelial cells which is dependent on
mTOR-p70S6k activity (Koehl et al., 2007). mTOR is involved in nutri-
ent signaling pathways that regulate longevity in various organisms
and mammals (Fontana et al., 2010). Rapamycin inhibition of mTOR
pathway increases mouse life span (Fontana et al., 2010). Rapamycin
is anti-angiogenetic as well (Guba et al., 2002).
DFT prophylaxis has been shown to reduce the incidence of VOD
in pediatric HSCT (Corbacioglu et al., 2012). Furthermore, DFT has
been demonstrated to exhibit therapeutic potential to treat severe
malaria (Francischetti et al., 2012). Finally, further preclinical and
clinical investigations are needed to assess the role of DFT in the
treatment of patients with multiple myeloma (Guglielmelli et al.,
2012).
Interestingly, drug safety evaluation of DFT has been recently
performed, displaying a safety proﬁle of such product (Richardson
et al., 2013).
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